Fredun Pharmaceuticals Hits New 52-Week High of Rs.1971.25 Marking Significant Milestone

On 18 Nov 2025, Fredun Pharmaceuticals recorded an intraday peak of Rs.1971.25, marking its highest price in the past year and an all-time high for the company. The stock opened with a gap up of 4.93%, continuing a three-day consecutive gain that has delivered a cumulative return of 15.57% over this period. Today’s performance outpaced its sector by 5.29%, underscoring the stock’s relative strength within the Pharmaceuticals & Biotechnology industry.

Fredun Pharmaceuticals is currently trading above all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, signalling sustained upward momentum. This technical positioning supports the stock’s recent rally and reflects positive investor sentiment based on underlying financial metrics.

The broader market context shows the Sensex opening 91.42 points higher but closing lower by 393.30 points at 84,649.07, down 0.36%. Despite this, the Sensex remains close to its own 52-week high of 85,290.06, just 0.76% away, and is trading above its 50-day moving average, which itself is positioned above the 200-day moving average, indicating a generally bullish trend in the market.

Fredun Pharmaceuticals’ one-year performance stands out with a return of 182.89%, significantly surpassing the Sensex’s 9.45% return over the same period. The stock’s 52-week low was Rs.635, illustrating a substantial appreciation in value over the past year. This performance is supported by the company’s financial results, which show a net sales growth rate of 39.73% annually and an operating profit growth rate of 55.03%.

In the quarter ending September 2025, Fredun Pharmaceuticals reported a net profit growth of 127.87%, contributing to a series of positive results over six consecutive quarters. Operating profit to interest ratio for the quarter reached 2.89 times, while profit before tax excluding other income stood at Rs.13.01 crore, reflecting a growth rate of 71.64%. Net sales for the quarter were Rs.145.30 crore, growing at 35.35% compared to previous periods.

The company’s return on capital employed (ROCE) is recorded at 20.2%, with an enterprise value to capital employed ratio of 3.3, indicating an attractive valuation relative to its capital base. Compared to its peers, Fredun Pharmaceuticals is trading at a discount to average historical valuations, which may be a factor in its recent market performance.

Over the past year, Fredun Pharmaceuticals has not only generated substantial returns but also demonstrated profit growth of 63.5%. The company’s PEG ratio stands at 0.5, reflecting the relationship between its price-to-earnings ratio and earnings growth rate. Additionally, the stock has outperformed the BSE500 index over the last three years, one year, and three months, indicating consistent market-beating performance in both the long and near term.

Despite the company’s size and performance, domestic mutual funds currently hold no stake in Fredun Pharmaceuticals. This absence of mutual fund ownership may reflect a cautious stance or valuation considerations within institutional circles, given their capacity for detailed research and on-the-ground analysis.

Fredun Pharmaceuticals’ recent milestone of reaching Rs.1971.25 as its 52-week high is a testament to its strong financial metrics and market momentum. The stock’s ability to sustain gains above key moving averages and outperform its sector highlights its current market position within the Pharmaceuticals & Biotechnology industry.

As the broader market navigates volatility, Fredun Pharmaceuticals’ performance stands out for its combination of growth in sales, profits, and valuation metrics. The company’s track record of positive quarterly results and attractive capital efficiency ratios contribute to the stock’s upward trajectory.

Limited Time Only! Subscribe for Rs. 12,999 and get 1 Year of MojoOne + an Additional Year Completely FREE. Don't miss out on this exclusive offer. Claim Your Free Year →